title: Comparison of streptokinase and urokinase in local thrombolysis of peripheral arterial occlusions for lower limb salvage.
abstract: OBJECTIVE
  To compare the efficacy and safety of streptokinase (SK) and urokinase (UK) in the treatment of local thrombolysis.
  
  
  METHODS
  Over a 24-month period, 40 patients with 45 lower limb arterial occlusions of less than 45 days duration underwent intraarterial fibrinolysis. Twenty occlusions were treated with recombinant UK and tissue culture-derived UK, and 25 occlusions were treated with SK. The study was retrospective, but the two groups were very homogeneous in terms of vascular surgical history, medical risk factors, and occlusion characteristics.
  
  
  RESULTS
  Complete lysis (95% or more) was achieved in 84% of SK infusions and 89% of UK infusions. Endoluminal and surgical interventions as well as clinical outcomes of SK and UK treatment were comparable. However, infusion time was significantly longer for SK treatment: 28.5 hours versus 19.1 hours for UK treatment (P = .035). Complication rates were not statistically significantly different. Average length of stay in the intensive care unit was identical (2.2 days) for both groups, and the difference in hospital stay was not statistically significant (7.7 days for SK vs 8.7 days for UK).
  
  
  CONCLUSIONS
  At the concentrations and doses used, the efficacy and safety of SK and UK were comparable, despite longer SK infusion time.
authors.affiliation: Department of Radiology, Hôtel-Dieu de Montréal Hospital, Quebec, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Dubé
authors.forename: G
authors.initials: G
authors.lastname: Soulez
authors.forename: E
authors.initials: E
authors.lastname: Thérasse
authors.forename: P
authors.initials: P
authors.lastname: Cartier
authors.forename: J F
authors.initials: JF
authors.lastname: Blair
authors.forename: P
authors.initials: P
authors.lastname: Roy
authors.forename: P
authors.initials: P
authors.lastname: Robillard
authors.forename: L
authors.initials: L
authors.lastname: Bruneau
authors.forename: P
authors.initials: P
authors.lastname: Van Nguyen
authors.forename: J R
authors.initials: JR
authors.lastname: Cusson
mesh_terms: D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery / Q000628:therapy; D003422:Critical Care; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007261:Infusions, Intra-Arterial; D007866:Leg / Q000098:blood supply*; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012189:Retrospective Studies; D012307:Risk Factors; D012449:Safety; D013300:Streptokinase / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods; D013997:Time Factors; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D013300:Streptokinase; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator